Back to results
US 8,313,950 B2Granted
Hepcidins as biomarkers for impending lupus nephritis flare
AssigneeThe Ohio State University Research Foundation
InventorsBrad H. Rovin, Xiaolan Zhang
Life of this patent
Estimating the term…
Abstract
Biomarkers for determining a kidney flare episode in systemic lupus erythematosus are described.
Claims7
A method of analyzing a subject sample to identify at least a beginning of a kidney flare episode in a subject suffering from systemic lupus erythematosus (SLE), comprising:
- i) assaying at least one urine sample from the subject for the amounts of hepcidin-20 and hepcidin-25, and
- ii) characterizing the subject's risk of having a kidney flare episode within about four months based upon the amounts of hepcidin-20 and hepcidin-25 measured in the at least one urine sample,
- wherein the subject is characterized as being at risk of having a kidney flare episode within about four months when there is an increase in hepcidin-20 and a decrease in hepcidin-25 in the at least one urine sample, as compared to predetermined threshold levels.
A diagnostic method, comprising:
- determining the concentrations of hepcidin-20 and hepcidin-25 in a urine sample from a subject suffering from systemic lupus erythematosus,
- and diagnosing the subject as being likely to suffer a kidney flare episode within about four months when the hepcidin-20 concentration in the urine sample is increased relative to a threshold hepcidin-20 concentration and the hepcidin-25 concentration in the urine sample is decreased relative to a threshold hepcidin-25 concentration;
- wherein a lack of an increase in hepcidin-20 in the sample relative to the threshold hepcidin-20 concentration and a lack of a decrease in hepcidin-25 concentration relative to the threshold hepcidin-25 concentration indicates that a kidney flare episode is not likely to occur in the subject within about four months.
Dependencies are inferred from the claim text.